Predictive biomarkers for bevacizumab in the first line treatment of ovarian cancer

被引：0
|
作者：
Jayson, Gordon [1 ,2 ]
机构：
[1] Christie Hosp, Manchester, Lancs, England
[2] Univ Manchester, Manchester M13 9PL, Lancs, England
来源：
ANGIOGENESIS | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
O-39
引用
收藏
页码：727 / 727
页数：1
相关论文
共 50 条
  • [1] Bevacizumab in the First-line Treatment of advanced Ovarian Cancer
    Mallmann, Michael R.
    Alakus, Hakan
    Mallmann, Peter
    Bruns, Christiane
    [J]. ONKOLOGE, 2019, 25 (11): : 1020 - 1021
  • [2] First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
    Marchetti, Claudia
    Muzii, Ludovico
    Romito, Alessia
    Panici, Pierluigi Benedetti
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 1095 - 1103
  • [3] SLOVENIAN EXPERIENCE WITH BEVACIZUMAB IN FIRST-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER
    Gregoric, B.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A53 - A54
  • [4] Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
    Conic, Irena
    Nedovic, Bojan
    Stojnev, Slavica
    Todorovska, Ilinka
    Dimitrijevic, Aleksandra
    Krstic, Miljan
    Djordjevic, Ivana
    Djordjevic, Biljana
    [J]. MEDICINA-LITHUANIA, 2022, 58 (05):
  • [5] Treatment preferences of patients with advanced ovarian cancer for the addition of bevacizumab to first line therapy
    Park, Y.
    Lee, J. Y.
    Nam, E. J.
    Kim, S.
    Kim, S. W.
    Kim, Y. T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 804 - 804
  • [6] BODY MASS INDEX AND BEVACIZUMAB IN FIRST LINE TREATMENT FOR ADVANCED OVARIAN CANCER (AOC)
    Petrillo, M.
    Paris, I.
    Amadio, G.
    Giovannoni, S.
    Salutari, V.
    Fagotti, A.
    Ricci, C.
    Ferrandina, M. G.
    Distefano, M.
    Scambia, G.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 687 - 687
  • [7] Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer
    Slaughter, Katrina N.
    Thai, Theresa
    Penaroza, Shayla
    Benbrook, Doris M.
    Thavathiru, Elangovan
    Ding, Kai
    Nelson, Tina
    McMeekin, D. Scott
    Moore, Kathleen N.
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 133 (01) : 11 - 15
  • [8] Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy
    Lee, Jung-Yun
    Kim, Kyunghoon
    Lee, Yun Shin
    Kim, Hyo Young
    Nam, Eun Ji
    Kim, Sunghoon
    Kim, Sang Wun
    Kim, Jae Weon
    Kim, Young Tae
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 143 (03) : 622 - 627
  • [9] First-line bevacizumab for ovarian cancer—new standard of care?
    Susana Banerjee
    Stan B. Kaye
    [J]. Nature Reviews Clinical Oncology, 2012, 9 : 194 - 196
  • [10] Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
    Ray-Coquard, I.
    Pautier, P.
    Pignata, S.
    Perol, D.
    Gonzalez-Martin, A.
    Berger, R.
    Fujiwara, K.
    Vergote, I.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Sehouli, J.
    Lorusso, D.
    Alia, E. M. Guerra
    Reinthaller, A.
    Nagao, S.
    Lefeuvre-Plesse, C.
    Canzler, U.
    Scambia, G.
    Lortholary, A.
    Marme, F.
    Combe, P.
    de Gregorio, N.
    Rodrigues, M.
    Buderath, P.
    Dubot, C.
    Burges, A.
    You, B.
    Pujade-Lauraine, E.
    Harter, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25): : 2416 - 2428
12345